Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...